Quality Improvement/Evidence of Therapy
This section describes current quality improvement and evidence of therapy programs of the Federal government related to chronic kidney disease.
Agency for Healthcare Research and Quality (AHRQ)
AHRQ databases of interest to the kidney community include the Medical Expenditure Panel Survey, Healthcare Cost and Utilization Project, National Guideline Clearinghouse, National Quality Measures Clearinghouse, and the Department of Health and Human Services (HHS) Measure Inventory (a repository of measures currently in use across HHS for quality measurement, improvement, and reporting). AHRQ also produces annual reports such as the National Healthcare Quality and Disparities Reports which may be of interest.
AHRQ has established Evidence-Based Practice Centers (EPCs) that produce evidence-based reports and technology assessments on a variety of clinical, behavioral, and organization and financing topics. These evidence reports may be used to inform guidelines, research agendas and quality measures, and serve as the basis for educational materials for consumers, clinicians and policymakers. Additionally, AHRQ leads the Accelerating Change and Transformation in Organizations and Networks (ACTION II) program. This is a model of field-based research designed to promote innovation in healthcare delivery by accelerating the diffusion of research into practice. One of the current ACTION II projects aims to implement and evaluate the Comprehensive Unit-based Safety Program to reduce preventable vascular-access infections in end-stage renal disease facilities. The Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) Network consists of research centers that conduct studies on the outcomes, effectiveness, safety, and usefulness of medical treatments, devices and services. Recent activity includes the completion of two studies funded by the American Recovery and Reinvestment Act (ARRA). Researchers at Johns Hopkins University studied the comparative effectiveness of antihypertensive medications on preventing morbidity and mortality in dialysis patients, early versus conventional initiation of dialysis therapy on cardiovascular and other patient outcomes, and iron management strategies on anemia management and other clinical outcomes. Researchers at the University of North Carolina at Chapel Hill compared intravenous iron formulations in end-stage renal disease. Overall this research resulted in approximately sixteen manuscripts, several of which have been published in major medical journals.
AHRQ continues to award extramural research grants to study chronic kidney disease, in areas such as patient safety, disease management and assessment in patients with multiple chronic conditions.
Dina Moss, MPA
ACTIONII Program Officer
Christine Chang, MD, MPH
Barbara Bartman, MD, MPH
Elizabeth M. Bishop, PhD, MS
National Healthcare Quality and Disparities Reports, Chronic Kidney Disease/End Stage Renal Disease and Diabetes
HHS Measure Inventory
Back to Top
This information was reviewed by KICC agency representatives. It may not reflect new or future agency activities. For more information, please contact the listed representatives.